TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03767205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Assist Robot
Description: 1. overground walking in three conditions (with robot-torque on/with robot-torque off/without robot). During overground walking, gait function was measured using motion analysis, sEMG, and force plate~2. treadmill waking in three conditions (with robot-torque on/with robot-torque off/without robot). During treadmill walking, the metabolic energy expenditure was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy).
Study: NCT05433948

Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous EEG and CRT
Description: EEG is recorded with 32 electrodes and commercial recording equipment.10 min EEG is recorded in idle mode with eyes closed prior to continuous EEG recording during the CRT examination, see below.~The test is performed via a laptop using EKHO software. The software generates 150 sound stimuli of 90 dB, which the patient hears in sound-insulated headphones. Via a push button in the dominant hand, the patient must respond as quickly as possible as soon as sounds are perceived.~PSE test: Duration 20 min. Includes 5 tasks: Digit-symbol Test, Number Connecting Test A, Number Connecting Test B, Serial Dotting Test and Line Tracing Test. Exits in 4 versions, which are used in repeated tests to avoid the learning effect. Scores range from -18 t0 6 and less -4 is abnormal.

Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous EEG and CRT
Description: EEG is recorded with 32 electrodes and commercial recording equipment.10 min EEG is recorded in idle mode with eyes closed prior to continuous EEG recording during the CRT examination, see below.~The test is performed via a laptop using EKHO software. The software generates 150 sound stimuli of 90 dB, which the patient hears in sound-insulated headphones. Via a push button in the dominant hand, the patient must respond as quickly as possible as soon as sounds are perceived.~PSE test: Duration 20 min. Includes 5 tasks: Digit-symbol Test, Number Connecting Test A, Number Connecting Test B, Serial Dotting Test and Line Tracing Test. Exits in 4 versions, which are used in repeated tests to avoid the learning effect. Scores range from -18 t0 6 and less -4 is abnormal.

Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous EEG and CRT
Description: EEG is recorded with 32 electrodes and commercial recording equipment.10 min EEG is recorded in idle mode with eyes closed prior to continuous EEG recording during the CRT examination, see below.~The test is performed via a laptop using EKHO software. The software generates 150 sound stimuli of 90 dB, which the patient hears in sound-insulated headphones. Via a push button in the dominant hand, the patient must respond as quickly as possible as soon as sounds are perceived.~PSE test: Duration 20 min. Includes 5 tasks: Digit-symbol Test, Number Connecting Test A, Number Connecting Test B, Serial Dotting Test and Line Tracing Test. Exits in 4 versions, which are used in repeated tests to avoid the learning effect. Scores range from -18 t0 6 and less -4 is abnormal.
Study: NCT00748540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrant Soundbridge
Description: Mixed and conductive hearing loss using round window stimulation
Study: NCT01373567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TINEFCON
Description: Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.
Study: NCT03264313

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Transcranial Magnetic Stimulation
Description: Patients undergoing of Deep Transcranial Magnetic Mtimulation (dTMS) for smoking cessation
Study: NCT01958736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ballistic Strength Training
Description: The experimental group will complete jump squats on the leg sled, single leg toe push offs (or bilateral where unable to complete single), alternating legs (i.e. bounding), mini tramp jumping, progressing to jogging, quick hip flexion and bounding on land.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Physiotherapy
Description: This group will complete a suite of exercises based upon existing rehabilitation practices that aim to improve mobility after stroke. The supervising physiotherapist will select and progress the exercises, recording the performance of exercises in an exercise log and detailing incidence of adverse events. Exercise selection will include: gait retraining, cardiovascular fitness, lower limb strengthening, static and dynamic balance.
Study: NCT01356602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab pre-filled syringe
Description: Canakinumab pre-filled syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canakinumab lyophilized powder
Description: Canakinumab lyophilized powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Triamcinolone Acetonide
Study: NCT04332380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma
Description: Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
Study: NCT05433948

Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous EEG and CRT
Description: EEG is recorded with 32 electrodes and commercial recording equipment.10 min EEG is recorded in idle mode with eyes closed prior to continuous EEG recording during the CRT examination, see below.~The test is performed via a laptop using EKHO software. The software generates 150 sound stimuli of 90 dB, which the patient hears in sound-insulated headphones. Via a push button in the dominant hand, the patient must respond as quickly as possible as soon as sounds are perceived.~PSE test: Duration 20 min. Includes 5 tasks: Digit-symbol Test, Number Connecting Test A, Number Connecting Test B, Serial Dotting Test and Line Tracing Test. Exits in 4 versions, which are used in repeated tests to avoid the learning effect. Scores range from -18 t0 6 and less -4 is abnormal.
Study: NCT02761434

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline (3% NaCl)
Description: 0.1 ml of 3% NaCl per kg of body weight per minute

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline (0.9% NaCl)
Description: 0.1 ml of 0.9% NaCl per kg of body weight per minute
Study: NCT02675712

Intervention type: OTHER
Intervention: African drumming
Description: Rhythmic beating or tapping of a variety of percussion instruments, which often occurs within a group setting
Study: NCT01356602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
Study: NCT02945449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wharton Jelly Mesenchymal stem cells
Description: Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
Study: NCT05433948

Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous EEG and CRT
Description: EEG is recorded with 32 electrodes and commercial recording equipment.10 min EEG is recorded in idle mode with eyes closed prior to continuous EEG recording during the CRT examination, see below.~The test is performed via a laptop using EKHO software. The software generates 150 sound stimuli of 90 dB, which the patient hears in sound-insulated headphones. Via a push button in the dominant hand, the patient must respond as quickly as possible as soon as sounds are perceived.~PSE test: Duration 20 min. Includes 5 tasks: Digit-symbol Test, Number Connecting Test A, Number Connecting Test B, Serial Dotting Test and Line Tracing Test. Exits in 4 versions, which are used in repeated tests to avoid the learning effect. Scores range from -18 t0 6 and less -4 is abnormal.

Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous EEG and CRT
Description: EEG is recorded with 32 electrodes and commercial recording equipment.10 min EEG is recorded in idle mode with eyes closed prior to continuous EEG recording during the CRT examination, see below.~The test is performed via a laptop using EKHO software. The software generates 150 sound stimuli of 90 dB, which the patient hears in sound-insulated headphones. Via a push button in the dominant hand, the patient must respond as quickly as possible as soon as sounds are perceived.~PSE test: Duration 20 min. Includes 5 tasks: Digit-symbol Test, Number Connecting Test A, Number Connecting Test B, Serial Dotting Test and Line Tracing Test. Exits in 4 versions, which are used in repeated tests to avoid the learning effect. Scores range from -18 t0 6 and less -4 is abnormal.
Study: NCT02720237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: In-person individual sessions (occurring one month apart) and booster phone sessions (occurring 2-3 weeks after each in-person session), delivered by a trained counselor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET) Intervention
Description: In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
Study: NCT03640858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova Dialyzer
Description: The Theranova dialyzer will be used for each of the hemodialysis treatments beginning week 3 and ending at the end of the dialysis week on week 14 and again starting week 23 and ending at the end of the dialysis week on week 46 . This will allow us to compare patient reported symptoms in weeks 1 and 2 when patients are on their usual dialyzer with their symptoms using the Theranova dialyzer. This will also allow us to see if there is a carry-over effect.
Study: NCT02394574

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clean Cookstove
Description: Ethanol

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Cookstove
Description: Firewood / Kerosene
Study: NCT03638089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fall-recovery training
Description: Participants practice recovering from simulated, treadmill-induced slips and trips.
Study: NCT02090114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
Study: NCT04378790

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patching
Description: Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glasses
Description: Eye Glasses are created and worn by patient to improve vision

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glasses
Description: Eye Glasses are created and worn by patient to improve vision
Study: NCT00846482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered once every 2 or 3 weeks
Study: NCT01469156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab 0.5 or 2.0 mg/0.05 cc
Description: ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 0.5 or 2.0 mg/0.05 cc
Description: ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.
Study: NCT01813227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: If you decide to participate in the study, in addition to the carfilzomib and possible dexamethasone administration, If less than a partial remission (PR) after 4 cycles is achieved, rituximab 375 mg/m2 on day 16 of each subsequent cycle will be added to the treatment. Subjects who meet the criteria for progression prior to 4 cycles of therapy will have rituximab 375 mg/m2 weekly for 4 consecutive weeks every 3 cycles added to the treatment. Subjects will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.~At the beginning of every cycle, your study doctor will see if your general health is satisfactory. You will be asked to report any side effects or problems you have had since the start of the last treatment cycle as well as any medication change(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.~You will also receive dexamethasone weekly on Days 1, 2, 8, 9, 15 and 16 starting with cycle 1 and continuing every cycle thereafter.
Study: NCT02858778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early order of palliative care consultation
Study: NCT02090114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.
Study: NCT02720237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) Intervention
Description: In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
Study: NCT04196751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Supervision
Description: After baseline data collection, participants will be invited to attend training on clinical supervision (CS). Education will be delivered in 3 phases. 1-Orientation to the CS model 2-Integration of theory into practice and 3-Skill advancement for supervisors. After training, participants will be encouraged to choose a supervisor, identify objectives for skill development. They will be advised to meet their supervisor once a month for 60 minutes (Due to COVID 19 pandemic the participants can have either one-to-one session in-person or virtually (Microsoft Team), however, if the supervisor and the supervisee working in the same campus can have their one-to-one session as per their preferences. Supervisor-supervisee will be working together to achieve the stated goals. Only the recorded attendance and nature of the session will be used for research purpose. Data will be collected at baseline, 6\&12 month with pre-specified tools.
Study: NCT03804255

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study: NCT04672616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Description: The intervention is a group psychotherapeutic offer for mentally burdened adolescents and young adults to support their professional integration.
Study: NCT00629174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Endurance and resistence training, 90 minutes, 3 times weekly

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental activity
Description: Participation at computer lessons, 3 times weekly, 90 minutes each
Study: NCT02866994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Connect Online
Description: Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCO PLUS
Description: Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family, as well as other women diagnosed with breast cancer
Study: NCT05019794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
Study: NCT02647437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Study: NCT02887794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical and psychoacoustic measures
Description: Our study focuses on psychoacoustic tests, specialist care protocols (psychotherapy, neuromodulation ...) being made independently of our study, as part of medical activity of Cerletti care unit or differentiated protocols. Thus, our study shows no individual benefit for the patient. However, a better understanding of the neurophysiological mechanisms underlying auditory hallucinatory phenomenon could allow a better management of these patients in the near future
Study: NCT02821650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEJ (Traditional stove to Efficient stove in Jhuggi)
Description: TEJ (means 'Bright' in Hindi) is an improved cook stove, locally designed and manufactured, aimed at reducing the indoor air emissions and improving health outcomes. 'Jhuggi' is a Hindi word which stands for a 'slum dwelling'
Study: NCT02214628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fovista® (anti-PDGF BB) plus anti-VEGF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fovista® (anti-PDGF BB) plus anti-VEGF
Study: NCT00563316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: The first infusion of panitumumab will occur on Cycle 1 Day 4. On Cycle 2 Day 1, panitumumab will be administered on the same day as irinotecan and every 2 weeks thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: The first infusion of irinotecan will occur on Cycle 1 Day 1. Irinotecan will be administered on the same day as panitumumab on Cycle 2 Day 1 and every 2 weeks thereafter.
Study: NCT02647437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02090114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.
Study: NCT04910165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Exparel used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
Study: NCT00828945

Intervention type: DEVICE
Intervention: Lipid Self Test
Description: Self test for lipid levels, twice during study period
Study: NCT03022890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hatha yoga
Description: 12 weeks of hour-long gentle hatha yoga classes

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: health education
Description: 12 weeks of hour-long classes on nutrition, sleep, coping with pain, and other health educaiton topics